Bispecific antibodies in multiple myeloma: Opportunities to enhance efficacy and improve safety

Last Updated: Wednesday, September 20, 2023

Bispecific antibodies (BsAbs) represent a new treatment option for patients with multiple myeloma, even in high-risk and heavily pretreated patients. This review considers ways to improve the activity of these new BsAb therapies, as well as ways to reduce the risk of serious side effects, including cytokine release syndrome.

Cancers (Basel)

Transplantation and Cellular Therapy

Patient-reported outcomes in long-term survivors of autologous hematopoietic cell transplantation in multiple myeloma

Cancer Discovery

CAR T-cell availability for multiple myeloma improving but still limited

Journal of the Advanced Practitioner in Oncology

Patient-reported outcomes with belantamab mafodotin treatment in patients with triple-class refractory multiple myeloma

European Journal of Haematology

Treatment sequences and drug costs from diagnosis to death in multiple myeloma

Platelets

Multiple myeloma and its treatment contribute to increased platelet reactivity

Transplantation and Cellular Therapy

Ethical challenges in CAR-T slot allocations

Nature

Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders

Clinical Journal of Oncology Nursing

Steroid-associated side effects: A symptom management update on multiple myeloma treatment

The Lancet

SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis

Blood

Final results from the first-in-human phase 1/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)

Multiple Myeloma Resource Center

Bispecific antibodies in multiple myeloma: Opportunities to enhance efficacy and improve safety

Transplantation and Cellular Therapy

Patient-reported outcomes in long-term survivors of autologous hematopoietic cell transplantation in multiple myeloma

Cancer Discovery

CAR T-cell availability for multiple myeloma improving but still limited

Journal of the Advanced Practitioner in Oncology

Patient-reported outcomes with belantamab mafodotin treatment in patients with triple-class refractory multiple myeloma

European Journal of Haematology

Treatment sequences and drug costs from diagnosis to death in multiple myeloma

Platelets

Multiple myeloma and its treatment contribute to increased platelet reactivity

Transplantation and Cellular Therapy

Ethical challenges in CAR-T slot allocations

Nature

Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders

Clinical Journal of Oncology Nursing

Steroid-associated side effects: A symptom management update on multiple myeloma treatment

The Lancet

SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis

Blood

Final results from the first-in-human phase 1/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)

Single Solitary Plasmacytoma to Active Myeloma

A Heavily Treated Relapsed/Refractory Multiple Myeloma Patient on Talquetamab

First Relapse of Multiple Myeloma Patient